2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Owen, W. F. Search for Related Content PubMed PubMed Citation Articles by Owen, W. F., Jr.

Patterns of Care for Patients with Chronic Kidney Disease in the United States: Dying for Improvement

Baxter Healthcare, Renal, Waukegan, Illinois; Duke Institute of Renal Outcomes Research and Health Policy, Duke University Medical Center, Durham, North Carolina.

Correspondence to Dr. William F. Owen, Jr., Chief Scientist, Baxter Healthcare, Renal, 1620 Waukegan Road, Waukegan, IL 60085-6730. Phone: 847-473-6307; Fax: 847-473-6903;

ABSTRACT. The burden of chronic kidney disease can be assessed by multiple criteria that underscore the need for improved detection, treatment, and outcome monitoring. Several process measures for the care of advanced CKD patients are examined herein. Twenty seven and 11% of patients with CKD in National Health and Nutrition Examination Surveys (NHANES) III had BP <140/90 and 130/85, respectively. In addition to inadequate prescription of antihypertensive drugs, another confounder is poor diagnostic recognition of CKD. Recent surveys of incident Medicare-eligible ESRD patients observed severe anemia in a preponderance of patients; mean and median hematocrit values were 27.7% ± 5.9 and 27.8%, respectively. Only 23 to 28% of these patients were prescribed epoetin alfa. Clinical practice guidelines recommend that <10% of maintenance hemodialysis patients should be chronically dialyzed using percutaneous catheters. A recent national survey of vascular access types among incident American hemodialysis patients found that 30%, 41%, and 29% were dialyzing through a catheter, prosthetic graft, and autologous fistula, respectively. Tunneled catheters are associated with a 39% annual increased risk of death. Based on pharmacokinetic assumptions about the minimum amount of solute clearance by hemodialysis needed for patient survival in ESRD, a GFR of 10.5 ml/min per 1.73 m² is needed. The mean GFR of incident ESRD patients in the United States was 9.5 ml/min per 1.73 m² in 2000. In addition to the wide international variability in modality treatment selection, geographic variability exists within the United States; <7 to >15% of the prevalent patients are treated by peritoneal dialysis across the country. Despite survival and quality-of-life benefits with transplantation, most eligible recipients in the United States have not been placed on a transplant waiting list 6 mo after beginning dialysis. Last, <40% of incident ESRD patients in the United States have received the recommended frequency of mammography, PAP examinations, or prostate-specific antigen (PSA) or HbA1c measurements. These deficiencies in care for patients with advanced CKD likely adversely influence the survival of US ESRD patients. Contemporary outcome information supports this contention. CKD patients referred to a nephrologist for the first time within 90 d of the start of dialysis have an approximately 40% to 60% increased risk of death during their first year of renal replacement therapy (RRT). Thirty-five percent of CKD patients are seen within 90 d of receiving RRT. In addition, if fewer than five nephrology visits occur, death risks are increased by 15%. These findings confirm the urgent need for improvement in healthcare delivery for CKD patient in the United States. E-mail: william_owen@baxter.com

This article has been cited by other articles:

				C. Zoccali, D. Abramowicz, J. B Cannata-Andia, P. Cochat, A. Covic, K.-U. Eckardt, D. Fouque, O. Heimburger, A. McLeod, E. Lindley, et al. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP) Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2162 - 2166. [Full Text] [PDF]

				H. Lu and C. Klaassen Gender Differences in mRNA Expression of ATP-Binding Cassette Efflux and Bile Acid Transporters in Kidney, Liver, and Intestine of 5/6 Nephrectomized Rats Drug Metab. Dispos., January 1, 2008; 36(1): 16 - 23. [Abstract] [Full Text] [PDF]

				A. A. Desai, A. M. Garber, and G. M. Chertow Rise of Pay for Performance: Implications for Care of People with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 1087 - 1095. [Abstract] [Full Text] [PDF]

				M. B. Patwardhan, G. P. Samsa, D. B. Matchar, and W. E. Haley Advanced Chronic Kidney Disease Practice Patterns among Nephrologists and Non-Nephrologists: A Database Analysis Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 277 - 283. [Abstract] [Full Text] [PDF]

				M. Yoshino, M. K. Kuhlmann, P. Kotanko, R. N. Greenwood, R. L. Pisoni, F. K. Port, K. J. Jager, P. Homel, H. Augustijn, F. T. de Charro, et al. International Differences in Dialysis Mortality Reflect Background General Population Atherosclerotic Cardiovascular Mortality J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3510 - 3519. [Abstract] [Full Text] [PDF]

				R. E. Bennett, R. M. DeHart, and S. A. Lauderdale Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2123 - 2127. [Abstract] [Full Text] [PDF]

				S. I. Hallan, J. Coresh, B. C. Astor, A. Asberg, N. R. Powe, S. Romundstad, H. A. Hallan, S. Lydersen, and J. Holmen International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2275 - 2284. [Abstract] [Full Text] [PDF]

				J.-L. Bascands and J. P. Schanstra Bradykinin and Renal Fibrosis: Have We ACE'd it? J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2504 - 2506. [Full Text] [PDF]

				J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF]

				Y. Liu Epithelial to Mesenchymal Transition in Renal Fibrogenesis: Pathologic Significance, Molecular Mechanism, and Therapeutic Intervention J. Am. Soc. Nephrol., January 1, 2004; 15(1): 1 - 12. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673